Skip to Content

M R7 (Rabeprazole Sodium Delayed-Release 20 mg)

Pill with imprint M R7 is Beige, Round and has been identified as Rabeprazole Sodium Delayed-Release 20 mg. It is supplied by Mylan Pharmaceuticals Inc..

Rabeprazole is used in the treatment of barrett's esophagus; erosive esophagitis; duodenal ulcer; duodenal ulcer prophylaxis; gerd and belongs to the drug class proton pump inhibitors. There is no proven risk in humans during pregnancy. Rabeprazole 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for M R7

Rabeprazole sodium delayed-release 20 mg M R7
Rabeprazole sodium delayed-release 20 mg M R7
Rabeprazole sodium delayed-release 20 mg M R7  Front
Rabeprazole sodium delayed-release 20 mg M R7  Back

Rabeprazole Sodium Delayed-Release

Imprint
M R7
Strength
20 mg
Color
Beige
Shape
Round
Availability
Prescription only
Drug Class
Proton pump inhibitors
Pregnancy Category
B - No proven risk in humans
CSA Schedule
Not a controlled drug
Labeler / Supplier
Mylan Pharmaceuticals Inc.
National Drug Code (NDC)
00378-6709

Get help with Imprint Code FAQs.

Related Images for "M R7"

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.